BNP Paribas Financial Markets’s Keros Therapeutics KROS Stock Holding History

BNP Paribas Financial Markets’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$533K	Buy	49,851 +42,947	+622%	+$478K	﹤0.01%	3721
2026 Q1	$76.2K	Buy	6,904 +2,590	+60%	+$40K	﹤0.01%	4501
2025 Q4	$87.8K	Sell	4,314 -64,342	-94%	-$1.13M	﹤0.01%	4437
2025 Q3	$1.09M	Buy	68,656 +22,057	+47%	+$326K	﹤0.01%	3071
2025 Q2	$622K	Sell	46,599 -35,337	-43%	-$477K	﹤0.01%	3188
2025 Q1	$835K	Buy	81,936 +35,826	+78%	+$416K	﹤0.01%	2904
2024 Q4	$730K	Buy	+46,110	New	+$2.4M	﹤0.01%	3039
2022 Q4	–	Sell	-22,427	Closed	-$844K	–	4341
2022 Q3	$844K	Buy	+22,427	New	+$777K	﹤0.01%	2616

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's KROS Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Keros Therapeutics (KROS) stake by 622% in Q2 2026, buying an estimated $478K and bringing the position to 49,851 shares worth $533K. The position accounts for ﹤0.01% of the portfolio, ranked #3721.

BNP Paribas Financial Markets first reported a position in KROS in Q3 2022 and has held it in 8 quarters since. The position peaked at $1.09M in Q3 2025. 122 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

BNP Paribas Financial Markets held 49,851 shares of Keros Therapeutics worth $533K as of Q2 2026.
BNP Paribas Financial Markets bought 42,947 Keros Therapeutics shares in Q2 2026, an estimated $478K.
Keros Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3721 holding.
BNP Paribas Financial Markets first reported a position in Keros Therapeutics in Q3 2022 and has held it in 8 quarters since.
BNP Paribas Financial Markets's Keros Therapeutics position peaked at $1.09M in Q3 2025.
122 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.